Humana Inc. (HUM) reported first-quarter 2025 adjusted earnings of $11.58 per share, which outpaced the Zacks Consensus Estimate by 16%. The bottom line soared 60.2% year over year. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Adjusted revenues improved 9.5% year over year to $32.1 billion. However, the top line missed the consensus mark by 0.3%. The quarterly results benefited on the back of strong premiums resulting from an expanding customer base in stand-alone prescription drug ...

Humana (HUM) reported $32.11 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 9.5%. EPS of $11.58 for the same period compares to $7.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $32.22 billion, representing a surprise of -0.33%. The company delivered an EPS surprise of +16.03%, with the consensus EPS estimate being $9.98.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Financial Performance - Humana's net income for Q1 2025 was $1.2 billion, or $10.30 per diluted share, compared to $0.7 billion, or $6.11 per diluted share in Q1 2024, reflecting a 68.1% increase [127]. - Total revenues increased by 8.4% to $32.1 billion in Q1 2025, up from $29.6 billion in Q1 2024, driven by an 8.0% rise in insurance premiums [133]. - The benefit ratio improved to 87.0% in Q1 2025 from 88.9% in Q1 2024, indicating better underwriting profitability [133]. - Operating costs rose by 11.1% to $3.4 billion in Q1 2025, compared to $3.0 billion in Q1 2024, reflecting increased administrative spending [133]. - Consolidated premiums revenue increased by $2.3 billion, or 8.0%, from $28.3 billion in the 2024 quarter to $30.5 billion in the 2025 quarter, driven by higher per member Medicare premiums and membership growth in stand-alone PDP and state-based contracts [135]. - Consolidated services revenue rose by $272 million, or 25.6%, from $1.1 billion in the 2024 quarter to $1.3 billion in the 2025 quarter, primarily due to growth in the primary care business [136]. - Consolidated benefits expense increased by $1.4 billion, or 5.6%, from $25.1 billion in the 2024 quarter to $26.5 billion in the 2025 quarter, with the consolidated benefit ratio decreasing by 190 basis points to 87.0% [138]. Membership and Segments - Approximately 3.5 million, or 67%, of individual Medicare Advantage members were in value-based relationships as of March 31, 2025, down from 69% a year earlier [126]. - Individual Medicare Advantage membership decreased by 333,100 members, or 6.0%, from March 31, 2024, to March 31, 2025, including a net decrease of 123,100 D-SNP members [149]. - Group Medicare Advantage membership increased by 21,100 members, or 3.8%, from March 31, 2024, to March 31, 2025 [150]. - State-based contracts and other membership increased by 346,700 members, or 27.5%, reflecting new contracts implemented in Oklahoma and Indiana [151]. - The CenterWell segment's revenue grew by 37.5% to $1.1 billion in Q1 2025, up from $0.8 billion in Q1 2024, highlighting strong performance in healthcare services [133]. - CenterWell segment income from operations increased by $0.1 billion, or 39.0%, from $0.3 billion in the 2024 quarter to $0.4 billion in the 2025 quarter [158]. - CenterWell services revenue increased by $0.3 billion, or 37.5%, from $0.8 billion in the 2024 quarter to $1.1 billion in the 2025 quarter, primarily due to growth in the primary care business [159]. Tax and Investment - The effective tax rate decreased slightly to 24.6% in Q1 2025 from 25.3% in Q1 2024, reflecting changes in tax liabilities [133]. - Investment income decreased by 8.3% to $264 million in Q1 2025, down from $288 million in Q1 2024, indicating challenges in investment performance [133]. - Investment income decreased by $24 million, or 8.3%, from $288 million in the 2024 quarter to $264 million in the 2025 quarter, mainly due to lower interest income on debt securities [137]. - The average duration of the investment portfolio was approximately 3.4 years as of March 31, 2025, indicating sensitivity to interest rate changes [191]. - The company experienced a net unrealized loss position of $1.1 billion on its investment portfolio as of March 31, 2025, down from a loss of $1.4 billion at December 31, 2024 [190]. Cash Flow and Capital Management - Cash and cash equivalents increased to approximately $4.3 billion at March 31, 2025, up from $2.2 billion at December 31, 2024 [163]. - Net cash provided by operating activities decreased to $331 million in the 2025 quarter from $423 million in the 2024 quarter, primarily due to unfavorable working capital impacts [164]. - Total net receivables rose to $4.459 billion at March 31, 2025, compared to $2.704 billion at December 31, 2024, reflecting higher Medicare premiums and membership growth [166]. - Total net capital expenditures, excluding acquisitions, were $95 million in the 2025 quarter, down from $177 million in the 2024 quarter [168]. - The company issued $750 million of 5.550% unsecured senior notes due May 1, 2035, and net proceeds from these offerings were $1.481 billion [171]. - The company repurchased common shares for $702 million in the 2024 quarter and paid dividends of $108 million in the 2025 quarter [176][177]. - Aggregate statutory capital and surplus of state-regulated subsidiaries was approximately $13.2 billion, exceeding minimum regulatory requirements of $11.4 billion [187]. - Future liquidity sources are expected to be adequate for ongoing operations, acquisitions, and capital expenditures for at least the next twelve months [182]. Strategic Focus - Humana's strategy focuses on integrated care delivery, aiming for long-term growth in membership and earnings through enhanced member engagement and data analytics [126]. - Charges related to value creation initiatives amounted to $24 million in Q1 2025, compared to $29 million in Q1 2024, primarily due to asset impairments and workforce optimization [119].

Humana (HUM) came out with quarterly earnings of $11.58 per share, beating the Zacks Consensus Estimate of $9.98 per share. This compares to earnings of $7.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.03%. A quarter ago, it was expected that this health insurer would post a loss of $2.24 per share when it actually produced a loss of $2.16, delivering a surprise of 3.57%.Over the last four quarters, the company has sur ...

Humana (HUM) Q1 2025 Earnings Call April 30, 2025 08:00 AM ET Company Participants Lisa Stoner - Vice President-Investor RelationsJames Rechtin - President & CEOCeleste Mellet - CFOBen Hendrix - Vice PresidentGeorge Renaudin - President of Medicare & Medicaid and DirectorAndrew Mok - DirectorA.J. Rice - Managing DirectorJoshua Raskin - Partner - Managed Care & ProvidersLance Wilkes - Managing DirectorLisa Gill - Managing DirectorDavid Windley - Managing Director Conference Call Participants Sarah James - An ...

Financial Data and Key Metrics Changes - The company reaffirmed its full-year guidance, indicating a strong start to 2025 with Q1 results ahead of plan [5][14] - Adjusted EPS guidance for the year is approximately $16.25, with an expected insurance segment benefit ratio of 90.1% to 90.5% [15][14] - G&A costs for the quarter were slightly better than expectations, attributed to the timing of costs expected in the second and third quarters [11][14] Business Line Data and Key Metrics Changes - The Medicare product and experience maintained membership guidance for 2025, with strong performance in the Open Enrollment Period (OEP) [8] - CenterWell and Medicaid businesses showed robust patient and membership growth, with 30 new centers added through acquisition and partnership [12][14] - The company reported a 30% to 50% reduction year over year in members with weight refills due to medication adherence campaigns [11] Market Data and Key Metrics Changes - The company is seeing strong year-to-date performance in markets with high concentrations of members, particularly in Florida, Illinois, and Texas [41] - Medicaid membership growth is on track, with approximately 100,000 growth year-to-date, aligning with the expected annual growth of 175,000 to 250,000 [74] Company Strategy and Development Direction - The company is focused on operational efficiencies, increasing flexibility, and operating leverage while making investments to improve member outcomes [14] - The integration between the insurance segment and CenterWell is aimed at delivering better health outcomes and improving STARS performance [58][60] - The company is committed to returning to a 3% pre-tax margin in Medicare Advantage (MA) by 2027, with ongoing focus on quality and operational excellence [48][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying progress of the business despite external challenges, emphasizing control over medical costs and operational efficiencies [50][52] - The company is monitoring changes in consumer behavior due to the Inflation Reduction Act (IRA) and is prepared for potential impacts on future performance [6][14] - Management highlighted the importance of navigating regulatory headwinds while focusing on controllable factors [51][52] Other Important Information - The company is actively working through STARS strategy and bids, with a focus on balancing membership and margins [32][33] - Recent fulfillment agreements with multiple companies are expected to contribute positively to growth [12][63] Q&A Session Summary Question: How much of your investments moved out of Q1? - Management indicated that most of the impact of incremental investments flowed through the MLR in Q1, with expectations for higher levels in the second through fourth quarters [20] Question: Update on the path to the 3% MA margin target? - Management reiterated focus on achieving the 3% margin, with timing tied to STARS outcomes, and no significant changes from previous communications [23] Question: Update on STARS initiatives and bids? - Management expressed confidence in progress made on STARS initiatives and ongoing work on bids, emphasizing a balanced approach to membership and margins [27][32] Question: Experience in Part D relative to expectations? - Trends in the business are consistent with expectations, with mid-single-digit growth on the medical side and low double-digit growth on the pharmacy side [36] Question: Visibility on risk adjustment and Group MA? - Management reported strong membership changes and visibility into risk adjustment, with no significant behavioral changes noted in Group MA [41][43] Question: Comments on Medicaid visibility and utilization? - Medicaid is performing in line with expectations, with strong growth and positive trends in member engagement and outcomes [75][76] Question: Clarification on GAAP EPS and valuation adjustments? - Management clarified that the adjustment in GAAP EPS guidance is unrelated to structural impairment and is part of a complex calculation [93]

Financial Performance - 1Q25 earnings per share (EPS) reported at $10.30 (GAAP) and $11.58 (Adjusted) compared to $6.11 and $7.23 in 1Q24, representing a year-over-year increase of 68% and 60% respectively[3] - Consolidated revenues for 1Q25 reached $32,112 million, up from $29,611 million in 1Q24, reflecting a year-over-year growth of 8.5%[8] - Humana's consolidated revenues for Q1 2025 reached $32,112 million, up from $29,611 million in Q1 2024, reflecting an increase of 8.4%[40] - Humana Inc. reported a net income of $1,242 million for Q1 2025, up from $739 million in Q1 2024, representing a 68% increase[64] - Total revenues for Q1 2025 reached $32,112 million, compared to $29,611 million in Q1 2024, marking an increase of 8.5%[65][66] Insurance Segment Performance - The Insurance segment reported revenues of $30,937 million in 1Q25, an increase from $28,699 million in 1Q24, marking a growth of 7.7%[20] - The Insurance segment reported revenues of $30,937 million in Q1 2025, compared to $28,699 million in Q1 2024, marking a growth of 7.7%[40] - The Insurance segment's benefit ratio improved to 87.4% in Q1 2025 from 89.3% in Q1 2024, indicating better cost management[41] - Income from operations for the Insurance segment increased significantly to $1,574 million in Q1 2025, up from $898 million in Q1 2024, representing a growth of 75.2%[45] - The benefit ratio improved to 87.0% in Q1 2025 from 89.3% in Q1 2024, indicating better cost management in claims[65][66] Membership and Enrollment - Individual Medicare Advantage annual membership is expected to decline by approximately 550,000 due to exiting unprofitable plans and counties[3] - The total Medicare Advantage membership decreased to 5,788.4 thousand as of March 31, 2025, down 5.1% from 6,100.4 thousand a year earlier[67] - Humana expects to see growth of approximately 200,000 in Medicare stand-alone PDP membership[56] Operational Efficiency - The benefit ratio for the Insurance segment improved to 87.4% in 1Q25 from 89.3% in 1Q24, indicating enhanced operational efficiency[20] - Days in claims payable (DCP) decreased to 38.8 days in 1Q25 from 42.5 days in 1Q24, indicating improved claims processing efficiency[15] - Humana's operating cost ratio for Q1 2025 was 10.6%, slightly higher than 10.4% in Q1 2024, with adjusted (non-GAAP) figures showing 10.5% versus 10.2%[42] - Operating expenses for Q1 2025 were $30,098 million, an increase from $28,375 million in Q1 2024, reflecting a rise of 6.1%[66] Cash Flow and Capitalization - Operating cash flows decreased to $331 million in 1Q25 from $423 million in 1Q24, primarily due to unfavorable working capital items[17] - Humana's cash and cash equivalents at the end of Q1 2025 were $4,250 million, down from $5,910 million at the end of Q1 2024[64] - The company reported a significant increase in proceeds from the issuance of senior notes, totaling $1,481 million in Q1 2025 compared to $2,232 million in Q1 2024[64] - Debt-to-total capitalization improved to 42.8% in 1Q25 from 45.1% in 1Q24, reflecting a stronger balance sheet[8] Future Projections - Humana affirms its Adjusted FY 2025 EPS guidance at approximately $16.25 while revising GAAP EPS guidance to approximately $14.68 from $15.88[6] - Total revenues for 2025 are expected to be between $126 billion and $128 billion, with the insurance segment contributing $121 billion to $123 billion[56] - The CenterWell segment is projected to generate revenues between $20.5 billion and $21.5 billion[56] - The benefit ratio for the insurance segment is projected to be between 90.1% and 90.5%[56] - Operating cost ratio for consolidated operations is expected to be between 11.3% and 11.7%[56] - Cash flows from operations are projected to be between $2.4 billion and $2.9 billion[56] Segment Growth - The CenterWell segment revenues increased to $5,095 million in 1Q25 from $4,818 million in 1Q24, driven by growth in the primary care business[27] - The CenterWell segment's income from operations rose to $392 million in Q1 2025, compared to $282 million in Q1 2024, reflecting a growth of 39.1%[47] - The number of primary care patients served grew to 417,800 as of March 31, 2025, up from 318,000 a year earlier, indicating a year-over-year growth of 31.4%[72] - The total number of de novo primary care centers increased to 136 in Q1 2025, compared to 113 in Q1 2024, marking a growth of 20.4%[72] - The company aims to expand its market presence through new primary care centers and enhanced pharmacy solutions, focusing on improving patient engagement and care quality[77]

Core Viewpoint - Humana Inc. is expected to report strong first-quarter 2025 results, with earnings projected at $9.98 per share and revenues at $32.22 billion, indicating significant year-over-year growth [1][3]. Financial Performance - The first-quarter earnings estimate reflects a 38% year-over-year increase, while revenues are expected to grow by 9.8% [1]. - For the current year, Humana's revenue consensus estimate stands at $126.55 billion, representing an 8% year-over-year rise, and the EPS consensus is $16.36, indicating a growth of approximately 0.9% [3]. Earnings Expectations - Humana has consistently beaten earnings estimates in the past four quarters, with an average surprise of 15.4% [3]. - The company has a positive Earnings ESP of +0.57% and a Zacks Rank of 3 (Hold), suggesting a likelihood of an earnings beat this quarter [4]. Revenue Drivers - Revenue growth in Q1 is anticipated to be driven by higher premiums, with the consensus estimate for premiums at $30.7 billion, reflecting an 8.6% year-over-year increase [5]. - Revenues from Medicare stand-alone PDPs are expected to reach $1.7 billion, indicating a substantial year-over-year increase of 110.8% [5]. Membership Trends - Despite the expected revenue growth, total medical memberships are projected to decline by 3.8% year-over-year, primarily due to decreases in individual Medicare Advantage units and ASO commercial memberships [6]. Operating Expenses - Total operating expenses for the Insurance segment are estimated to grow by 7.6% year-over-year, attributed to higher operating costs [7].

Core Insights - Humana (HUM) is expected to report quarterly earnings of $9.98 per share, reflecting a 38% increase year over year, with revenues projected at $32.22 billion, a 9.8% increase from the previous year [1] - The consensus EPS estimate has been revised upward by 3.4% over the past 30 days, indicating analysts' positive reassessment of the company's performance [1][2] Revenue Estimates - Analysts estimate 'Revenues- Premiums' to be $30.68 billion, representing an 8.6% year-over-year increase [4] - 'Revenues- Services' are projected to reach $1.20 billion, indicating a 12.8% increase year over year [4] - 'Revenues- Investment income (loss)' is expected to be $275.11 million, reflecting a 4.5% decrease year over year [4] - 'Revenue- Insurance' is forecasted to be $31.15 billion, showing an 8.5% increase from the year-ago quarter [5] Membership Metrics - 'Medical Membership - Medicare stand-alone PDP' is expected to reach 2.45 million, up from 2.35 million in the same quarter last year [6] - 'Medical Membership- State-based contracts and other' is projected at 1.5 million, compared to 1.26 million in the previous year [6] - 'Medical Membership - Group Medicare Advantage' is estimated at 557.22 thousand, slightly up from 551.5 thousand year over year [7] - 'Medical Membership - Medicare Supplement' is forecasted at 375.88 thousand, an increase from 323.2 thousand in the previous year [7] - 'Medical Membership - Individual Medicare Advantage' is expected to be 5.2 million, down from 5.55 million year over year [7] - Total 'Medical Membership - Medicare' is projected to reach 8.21 million, down from 8.45 million in the previous year [8] - 'Medical Membership - Military services' is expected to be 5.32 million, down from 5.96 million in the same quarter last year [8] Stock Performance - Humana shares have shown a return of -0.1% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [9] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the overall market [9]

Company Overview - Humana (HUM) is expected to report quarterly earnings of $9.98 per share, reflecting a year-over-year increase of +38% [3] - Revenues are anticipated to reach $32.22 billion, which is a 9.8% increase from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for April 30, 2025, and could influence stock movement based on whether actual results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 3.41% higher in the last 30 days, indicating a more optimistic outlook from analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP for Humana is +0.57%, suggesting a potential positive deviation from the consensus estimate [11] - However, Humana currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Humana was expected to post a loss of $2.24 per share but actually reported a loss of $2.16, resulting in a surprise of +3.57% [12] - Over the past four quarters, Humana has successfully beaten consensus EPS estimates four times [13] Industry Context - In the Zacks Medical - HMOs industry, Centene (CNC) is projected to report earnings of $2.36 per share, marking a year-over-year increase of +4.4% [17] - Centene's revenue is expected to be $43.47 billion, up 7.6% from the previous year [17] - The consensus EPS estimate for Centene has been revised 1.7% lower, but a higher Most Accurate Estimate results in an Earnings ESP of 8.17%, indicating a likely earnings beat [18]